Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A nationwide non-medical switch from originator inflixima... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
0
Authors
Bente Glintborg
23 more
Bente Glintborg
•
Henrik Nordin
21 more
•
Merete Hetland
Published
May 4, 2017
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Annals of the Rheumatic Diseases
Topics
Medicine
Immunology
Internal Medicine
Rheumatology
Economics And Econometrics
Show all topics
DOI
10.1136/annrheumdis-2016-210742
